Rifabutin Prophylaxis and Uveitis
- 5 May 1994
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 330 (18) , 1315-1316
- https://doi.org/10.1056/nejm199405053301816
Abstract
Nightingale et al. (Sept. 16 issue)1 reported no cases of uveitis among 292 patients taking 300 mg of rifabutin per day as prophylaxis against Mycobacterium avium complex infection, and there was no mention of uveitis in the guidelines on treatment and prophylaxis for M. avium complex disease (Sept. 16 issue)2. However, Shafran and colleagues (Feb. 10 issue)3 reported the development of uveitis in 39 percent of 59 patients treated for M. avium complex bacteremia with 600 mg of rifabutin daily (along with clarithromycin and ethambutol). We report a case of bilateral uveitis in a patient who was taking the currently recommended daily dose of 300 mg of rifabutin for M. avium complex prophylaxis.Keywords
This publication has 4 references indexed in Scilit:
- Uveitis and Pseudojaundice During a Regimen of Clarithromycin, Rifabutin, and EthambutolNew England Journal of Medicine, 1994
- Recommendations on Prophylaxis and Therapy for Disseminated Mycobacterium avium Complex Disease in Patients Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1993
- Two Controlled Trials of Rifabutin Prophylaxis against Mycobacterium avium Complex Infection in AIDSNew England Journal of Medicine, 1993
- Dose-limiting toxicity of rifabutin in AIDS-related complexAIDS, 1990